The World Health Organisation (WHO) says that around 50 million people across the world suffer from epilepsy which makes it one of the most common neurological diseases. Read on as an expert shares ...

Seizures in newborns are one of the most frequent acute neurological conditions among infants admitted to neonatal care units.

Seizures in newborns are one of the most frequent acute neurological conditions among infants admitted to neonatal care units. A study published in Developmental Medicine & Child Neurology indicates ...

One in five or 20 per cent of newborns with neonatal seizures will go on to develop epilepsy by age one, finds a study on ...

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...

Join the epilepsy community for Purple Day® on March 26, a global initiative to raise epilepsy awareness and support the millions of people living with epilepsy worldwide. Approximately 65 million ...

Andrew Wilner speaks with fellow neurologist Karine Abou Khaled about her recent study on a 15-minute subdermal EEG with a simplified module for critically ill patients vs a full-head 24-hour EEG.

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...